“
“PS/EPDM blends prepared by in situ-polymerization of styrene in the presence of EPDM are immiscible and show two phases. Furthermore, the dynamic mechanical behavior of injected specimens is quite different from that of noninjected blends. This is attributed to the differences in morphology before and after injection molding. The morphology of the noninjected

blends consists of PS spherical domains covered by a thin layer of EPDM, whereas the injected blends show elastomeric dispersed phase morphology in a rigid matrix. SEM analysis was important to elucidate the changes in the dynamic mechanical behavior of PS/EPDM blends, but TEM analysis is more precise for morphological characterization and yielded the real average diameter of EPDM particles. Comparing the average diameters for the PS/EPDM blends obtained from SEM and TEM analyses, the diameters obtained from the SEM analysis are wider than those of TEM which is due to the solvent extraction effect oil the blend morphology. Temsirolimus (C) 2009 Wiley Periodicals, Inc. J Appl Polym Sci 112: 2280-2289, 2009″
“Background: The use of anti-malarial drug combinations with artemisinin or with one of its derivatives is now widely recommended to overcome drug resistance in falciparum as well as vivax malaria. The fixed oral dose artemisinin-naphthoquine combination (ANQ, ARCO (TM)) is a newer artemisinin-based combination (ACT) therapy undergoing

clinical assessment. A study was undertaken to assess the safety, efficacy and tolerability of ANQ combination in areas of multi-drug resistance to generate preliminary baseline data in adult population of Papua New Guinea.

Methods: The clinical assessment was an open-labeled, AZD1152 mouse two-arm, randomized study comparing ANQ combination as a single dose regimen and three days regimen (10 mg/kg/day) of chloroquine plus single dose sulphadoxine-pyrimethamine (CQ+SP) for the treatment of uncomplicated falciparum malaria with 28 days follow-up in an adult population. The primary outcome measures for efficacy were day 1, 2, 3 7, 14 and 28-day cure rates. Secondary outcomes included selleck inhibitor parasite clearance time, fever clearance time, and gametocyte carriage. The main outcome measures

for safety were incidences of post-treatment clinical and laboratory adverse events.

Results: Between June 2005 and July 2006, 130 patients with confirmed uncomplicated P. falciparum were randomly assigned to receive ANQ and CQ+SP, only 100 patients (51 in ANQ group and 49 in CQ+SP group) were evaluated for clinical and parasitological outcomes. All the patients treated with ANQ and CQ+SP showed adequate clinical and parasitological response with 28 days follow-up. The cure rate for ANQ on day 1, 2, 3, 7, 14, and 28 was 47%, 86%, 92%, 94%, 94% and 94%, respectively. Recrudescence account for 6%; all were cleared on day 21. For CQ+SP treated group the cure rates were 24%, 67%, 82%, 82%, 84% and 88%, respectively. Recrudescence accounted for 10%; all were cleared on day 28 except for one patient.